ProShare Advisors LLC lifted its stake in Core Laboratories N.V. (NYSE:CLB) by 2.3% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,889 shares of the oil and gas company’s stock after buying an additional 87 shares during the period. ProShare Advisors LLC’s holdings in Core Laboratories N.V. were worth $394,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of CLB. State Board of Administration of Florida Retirement System grew its position in shares of Core Laboratories N.V. by 11.8% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 2,834 shares of the oil and gas company’s stock valued at $327,000 after buying an additional 300 shares during the last quarter. Bank of New York Mellon Corp grew its position in shares of Core Laboratories N.V. by 4.1% in the 1st quarter. Bank of New York Mellon Corp now owns 238,602 shares of the oil and gas company’s stock valued at $27,564,000 after buying an additional 9,420 shares during the last quarter. UBS Asset Management Americas Inc. grew its position in shares of Core Laboratories N.V. by 14.7% in the 1st quarter. UBS Asset Management Americas Inc. now owns 131,613 shares of the oil and gas company’s stock valued at $15,204,000 after buying an additional 16,882 shares during the last quarter. Karp Capital Management Corp purchased a new position in shares of Core Laboratories N.V. in the 1st quarter valued at $620,000. Finally, Ameriprise Financial Inc. grew its position in shares of Core Laboratories N.V. by 18.5% in the 1st quarter. Ameriprise Financial Inc. now owns 46,807 shares of the oil and gas company’s stock valued at $5,406,000 after buying an additional 7,298 shares during the last quarter.

Shares of Core Laboratories N.V. (CLB) opened at 94.26 on Friday. The stock has a 50 day moving average of $93.57 and a 200 day moving average of $102.76. Core Laboratories N.V. has a 1-year low of $86.55 and a 1-year high of $125.83. The firm has a market cap of $4.16 billion, a PE ratio of 57.83 and a beta of 1.64.

Core Laboratories N.V. (NYSE:CLB) last released its quarterly earnings results on Monday, July 24th. The oil and gas company reported $0.52 EPS for the quarter, topping the consensus estimate of $0.51 by $0.01. The business had revenue of $163.90 million during the quarter, compared to analyst estimates of $168.23 million. Core Laboratories N.V. had a net margin of 11.80% and a return on equity of 49.29%. The company’s quarterly revenue was up 10.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.35 earnings per share. Equities research analysts anticipate that Core Laboratories N.V. will post $1.99 earnings per share for the current fiscal year.

WARNING: This report was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/10/08/proshare-advisors-llc-grows-holdings-in-core-laboratories-n-v-clb.html.

A number of research analysts recently commented on the stock. ValuEngine downgraded shares of Core Laboratories N.V. from a “hold” rating to a “sell” rating in a research report on Friday, September 1st. Cowen and Company set a $100.00 target price on shares of Core Laboratories N.V. and gave the company a “hold” rating in a research report on Friday. Zacks Investment Research downgraded shares of Core Laboratories N.V. from a “hold” rating to a “strong sell” rating in a research report on Monday, July 17th. BidaskClub downgraded shares of Core Laboratories N.V. from a “hold” rating to a “sell” rating in a research report on Monday, July 31st. Finally, UBS AG reissued a “neutral” rating and set a $110.00 price objective (down from $125.00) on shares of Core Laboratories N.V. in a research report on Wednesday, July 26th. Four equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and four have given a buy rating to the company. Core Laboratories N.V. has an average rating of “Hold” and a consensus target price of $111.10.

Core Laboratories N.V. Company Profile

Core Laboratories N.V. provides reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company operates through three segments: Reservoir Description, Production Enhancement and Reservoir Management. The Reservoir Description segment encompasses the characterization of petroleum reservoir rock, fluid and gas samples.

Want to see what other hedge funds are holding CLB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Core Laboratories N.V. (NYSE:CLB).

Institutional Ownership by Quarter for Core Laboratories N.V. (NYSE:CLB)

Receive News & Stock Ratings for Core Laboratories N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories N.V. and related stocks with our FREE daily email newsletter.